TY  - JOUR
AU  - De Vita, Elena
AU  - Schüler, Peter
AU  - Lovell, Scott
AU  - Lohbeck, Jasmin
AU  - Kullmann, Sven
AU  - Rabinovich, Eitan
AU  - Sananes, Amiram
AU  - Heßling, Bernd
AU  - Hamon, Veronique
AU  - Papo, Niv
AU  - Hess, Jochen
AU  - Tate, Edward W
AU  - Gunkel, Nikolas
AU  - Miller, Aubry
TI  - Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.
JO  - Journal of medicinal chemistry
VL  - 61
IS  - 19
SN  - 1520-4804
CY  - Washington, DC
PB  - ACS
M1  - DKFZ-2018-01772
SP  - 8859 - 8874
PY  - 2018
AB  - Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity-based probe, could be used to pull down active endogenous KLK6.
LB  - PUB:(DE-HGF)16
C6  - pmid:30212625
DO  - DOI:10.1021/acs.jmedchem.8b01106
UR  - https://inrepo02.dkfz.de/record/141252
ER  -